AIFA adds Ranluspec to simplified anti-VEGF monitoring form for four eye indications
From 4 November 2026, registry users can select Ranluspec (ranibizumab) in AIFA's simplified multi-drug intravitreal anti-VEGF monitoring form, following Determination Pres/1459/2026.
Italy's medicines agency AIFA has updated its simplified multi-drug monitoring form for intravitreal anti-VEGF treatments so that Ranluspec (ranibizumab) can now be chosen within it. The change applies from 4 November 2026.
AIFA says the update follows the entry into force of Determination Pres/1459/2026, notice of which appeared in Italy's Official Gazette (Gazzetta Ufficiale) no. 256 on 3 November 2026. The determination is available as a PDF on the agency's website.
Ranluspec can be selected for four indications: neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular oedema (DME); visual impairment due to macular oedema secondary to retinal vein occlusion, either branch or central (RVO); and visual impairment due to choroidal neovascularisation (CNV).
The notice was issued by AIFA's Monitoring Registries Office and is addressed to users of the Registries of Medicines Subject to Monitoring. The source does not give further detail on reimbursement terms or the content of the determination beyond the registry change.
What it means for your team
- Prescribers and registry users in Italy can now record Ranluspec treatment through the simplified multi-drug anti-VEGF intravitreal form for AMD, DME, RVO and CNV.
- Market-access and reimbursement teams handling ranibizumab should check Determination Pres/1459/2026 for the underlying conditions, as the notice itself is purely administrative.
- Hospital pharmacy and registry administrators may need to confirm that internal workflows reflect the new selectable option from 4 November 2026.
Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.
Market accessCompany releaseMedicare begins paying for Lucid's EsoGuard as PAVmed's Veris nears FDA 510(k) filing
Market accessOfficialDenmark updates Voltabak eye drop supply notice, with shortage expected to run to mid-May 2027
Market accessOfficialMethergin 0.2 mg/ml injection withdrawn from Danish market, DKMA reports
Market accessOfficialDenmark updates import window for estradiol 25 microgram patches in supply failure
Market accessOfficialDKMA updates Vivelle Dot 37.5 supply notice: shortage expected to last until end of December
Market accessOfficial